SLC5A2 and prediabetes syndrome: Empagliflozin treatment ameliorated left ventricle reverse remodeling, enhancing patient ejection fraction [161], while a recent meta-analysis described the potentialities of SGLT2 inhibitors in preventing the evolution from prediabetes to DM [162].